Mibefradil是一种新型钙拮抗剂,其结构及作用机制与以往的钙拮抗剂不同,可选择性阻滞T型钙通道,药理作用时间长,且无抑制心肌收缩力、激活交感系统引起心率增快和水肿等副作用。本文对该药的药理学,它对高血压和心绞痛的治疗情况及其安全性做了综述。 Mibefradil is a new type of calcium antagonist. Its structure and mechanism of action is different from previous calcium antagonists. It selectively blocks T-type calcium channels and has long pharmacological action. It does not inhibit myocardial contractility, and activates the sympathetic system to cause increased heart rate Fast and edema and other side effects. This article describes the pharmacology of this medicine, its treatment of hypertension and angina, and its safety.